5-Amino-1MQ Side Effects: Safety Signals and Warnings
5-Amino-1MQ safety concerns are compound-specific. The main listed side effects are Limited safety data, No significant adverse effects reported in preclinical studies, and Potential for off-target methyltransferase inhibition at high doses (theoretical). The main warning signals are No human clinical trials completed, Technically a small molecule, not a peptide - regulatory classification differs, and Long-term safety profile unknown.
Direct Answer
Evidence for 5-Amino-1MQ is too preliminary to support a research protocol with confidence. All published data is from mouse models in a single research group, with no human pharmacokinetic data and no independent replication. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or tesofensine have vastly stronger evidence bases as starting points.
- Evidence grade
- Level D
- Research status
- Preclinical
- Category
- Weight Loss & Metabolic
- Evidence context
- NNMT inhibition mechanistic research (preclinical only)
Reported Side Effects
- Limited safety data
- No significant adverse effects reported in preclinical studies
- Potential for off-target methyltransferase inhibition at high doses (theoretical)
Warnings
- No human clinical trials completed
- Technically a small molecule, not a peptide - regulatory classification differs
- Long-term safety profile unknown
- Quality and purity of commercially available product highly variable
Known or Plausible Interactions
- NAD+ precursors like NMN and NR (potential synergistic effects on NAD+ levels)
- Sirtuin activators such as resveratrol (may have additive metabolic effects)
Regulatory Context
Not FDA-approved. Human use has no established regulatory authorization, and product identity outside documented research settings is uncertain.
Evidence Snapshot
| Evidence grade | Level D |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Fat Mass Reduction (Level D) and NAD+ and Metabolic Enhancement (Level D) |
| Primary citation count | 2 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of 5-Amino-1MQ?
5-Amino-1MQ safety concerns are compound-specific. The main listed side effects are Limited safety data, No significant adverse effects reported in preclinical studies, and Potential for off-target methyltransferase inhibition at high doses (theoretical). The main warning signals are No human clinical trials completed, Technically a small molecule, not a peptide - regulatory classification differs, and Long-term safety profile unknown.
What is the evidence level for 5-Amino-1MQ?
5-Amino-1MQ is rated Level D. Its current research status is Preclinical.
What is 5-Amino-1MQ best known for?
NNMT inhibition mechanistic research (preclinical only).
Where can I read the full 5-Amino-1MQ evidence review?
The full evidence review is available at https://examinepeptides.com/library/5-amino-1mq.
Related Guides
How to Cite This Page
ExaminePeptides. "5-Amino-1MQ Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/5-amino-1mq-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.